| [1] |
Li J, Liu Y, Jiang Y, et al. Breast cancer-specific mortality pattern and its changing feature according to estrogen receptor status in two time periods[J]. PLoS One,2016,11(6):e0157322.
|
| [2] |
Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer:20 year follow-up of the EORTC 10801 phase 3 randomised trial[J]. Lancet Oncol,2012,13(4):412-419.
|
| [3] |
van Maaren MC, de Munck L, de Bock GH, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a populationbased study[J]. Lancet Oncol,2016,17(8):1158-1170.
|
| [4] |
Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer [J]. J Clin Oncol, 2014,32(14):1507-1515.
|
| [5] |
Bodilsen A, Bjerre K, Offersen BV, et al. Importance of margin width in breast-conserving treatment of early breast cancer[J]. J Surg Oncol,2016,113(6):609-615.
|
| [6] |
Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ[J]. Ann Surg Oncol,2016,23(12):3801-3810.
|
| [7] |
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18[J]. J Clin Oncol,1997,15(7):2483-2493.
|
| [8] |
Hyslop T, Alvarado M, Forero A, et al. Abstract S3-06:Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017[J]. Cancer Res, 2016, 76 (4 Suppl): Abstract S3-06.
|
| [9] |
中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015 版)[J].中国癌症杂志,2015,25(9):692-754.
|
| [10] |
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases(IBCSG 23-01): a phase 3 randomised controlled trial[J]. Lancet Oncol,2013,14(4):297-305.
|
| [11] |
邵志敏,李俊杰.2015 年St. Gallen 国际乳腺癌研讨会乳腺癌新的诊疗理念[J/CD].中华乳腺病杂志(电子版),2015,9(2):65-69.
|
| [12] |
Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance)ACOSOG Z0011 Randomized Trial[J]. Ann Surg,2016,264(3):413-420.
|
| [13] |
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer(EORTC 10981-22023 AMAROS): a randomised, multicentre, openlabel, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014,15(12):1303-1311.
|
| [14] |
Li JW, Mo M,Yu KD,et al. ER-poor and HER2-positive:a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy[J]. PLoS One,2014,9(12):e114646.
|
| [15] |
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy(SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol,2013,14(7):609-618.
|
| [16] |
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study[J]. J Clin Oncol,2015,33(3):258-264.
|
| [17] |
Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node Identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance)[J].Ann Surg,2015,261(3):547-552.
|